NICE TA1140 final guidance recommends ruxolitinib cream for non-segmental vitiligo after rapid review
NICE issued TA1140 on 17 March 2026 recommending ruxolitinib cream for non-segmental vitiligo with facial involvement in people aged 12 years and over. The committee relied on pooled phase 3 TRuE-V direct evidence and reviewed a phototherapy indirect comparison that informed pathway positioning but remained too uncertain for robust cost-utility anchoring.
Cross-domain NMA transitivity stress-testing: a March 2026 playbook for decision teams
Recent PubMed network meta-analysis publications across pharmacotherapy, surgery, and procedure-plus-medication pathways show why decision teams need explicit transitivity stress tests before converting rank outputs into reimbursement narratives.
Outcome-measurement heterogeneity is now a first-order ITC and NMA submission risk
A 15 March 2026 meta-analytic review reports rising outcome-measurement heterogeneity and measurable treatment-estimate shifts across depression psychotherapy trials. For HTA teams, the immediate operational response is endpoint governance by design: protocol-level mapping rules, instrument-stratified sensitivity plans, and audit-traceable assumption control across ITC, MAIC, and NMA workflows.
NICE TA1121 recommends acoramidis and formalises a comparator-bridge evidence standard in transthyretin cardiomyopathy
NICE recommended acoramidis for transthyretin amyloidosis with cardiomyopathy on 14 January 2026, using indirect comparative evidence to position acoramidis against tafamidis in routine NHS use.
SMC accepts Alyftrek for restricted NHSScotland use, with evidence lineage anchored in active-comparator CFTR-modulator studies
On 9 March 2026, SMC accepted vanzacaftor/tezacaftor/deutivacaftor for restricted use in NHSScotland for people aged 6 years and older with at least one F508del mutation, with clinical lineage drawn from European Medicines Agency direct comparative study evidence.
SMC submission-route mix in March 2026 signals a four-lane evidence architecture for faster HTA readiness
SMC records published on 9 March 2026 show mixed submission routes in one cycle, highlighting the need for route-specific evidence operations that align clinical, economic, and timeline controls before filing.
Anchored Comparator Governance Is Back: What This Week of ITC and NMA Publications Means for Evidence Teams
Recent PubMed indexed evidence synthesis publications show a renewed emphasis on anchored comparator design and transparent assumptions. This article translates that seven day signal into a concrete governance playbook for HTA facing evidence teams.
SMC accepts vorasidenib for IDH-mutant grade 2 glioma with phase III direct evidence and PAS-linked value conditions
SMC accepted vorasidenib for eligible grade 2 astrocytoma or oligodendroglioma, citing randomized phase III progression-free survival benefit and linking cost-effectiveness to an approved patient access scheme.
EMA updates Ixchiq safety language after PRAC review identifies aseptic meningitis risk beyond older adults
EMA PRAC recommended updating Ixchiq product information after reviewing aseptic meningitis reports, including a case in a healthy young adult, reinforcing dynamic benefit-risk management for chikungunya vaccination decisions.
AbangeLabs ITC Studio: From MAIC-Centric Workflow to a Three-Ecosystem ITC Architecture
AbangeLabs ITC Studio has evolved from a MAIC-centric environment into an integrated architecture spanning MAIC, STC, and frequentist NMA, with data-readiness, governance checkpoints, and AI-supported reporting designed for audit-traceable evidence operations.
AbangeLabs